← Back to Search

Diuretic

Part A; Cohort 3 for Alzheimer's Disease

Phase 1
Waitlist Available
Research Sponsored by NeuroPro Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective in humans.

Eligible Conditions
  • Alzheimer's Disease
  • Epilepsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with abnormal ECG
Number of participants with abnormal lab test results
Number of participants with abnormal vital signs
+1 more
Secondary outcome measures
Dose proportionality
Pharmacokinetic AUCinf
Pharmacokinetic AUClast
+5 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: Part B; Cohort 3Experimental Treatment1 Intervention
Every 12-hour dosing of 80mg (7 days)
Group II: Part B; Cohort 2Experimental Treatment1 Intervention
Every 12-hour dosing of 40mg (7 days)
Group III: Part B; Cohort 1Experimental Treatment1 Intervention
Every 12-hour dosing of 20mg (7 days)
Group IV: Part A; Cohort 3Experimental Treatment1 Intervention
QD dosing of 160mg (1 day)
Group V: Part A; Cohort 2Experimental Treatment1 Intervention
QD dosing of 50mg (1 day)
Group VI: Part A; Cohort 1Experimental Treatment1 Intervention
QD dosing of 10mg (1 day)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NPT 2042 (bumetanide analog) or Matching Placebo
2022
Completed Phase 1
~50

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

NeuroPro Therapeutics, Inc.Lead Sponsor
~19 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top